China Cleared Jaypirca in Frontline CLL on a Win Over Chemotherapy and Non-Inferiority to Ibrutinib
- China’s NMPA has approved Jaypirca (pirtobrutinib), Eli Lilly‘s non-covalent BTK inhibitor, as monotherapy for adults with CLL or SLL across all lines of therapy and regardless of prior covalent BTK inhibitor treatment, Innovent Biologics, which sells the drug in mainland China, said on 28 September 2026.
- In BRUIN CLL-313, 282 untreated patients without 17p deletion were randomised to pirtobrutinib or bendamustine plus rituximab. Pirtobrutinib cut the risk of progression or death by 80.1% (HR 0.199) on independent review.
- In BRUIN CLL-314, 662 BTK inhibitor-naive patients, untreated or relapsed, were randomised to pirtobrutinib or ibrutinib. It met non-inferiority on overall response rate, with a numerically higher rate; progression-free survival is immature, with a trend in its favour.
- Innovent says CLL occurs at about 0.39 per 100,000 people in China, against roughly 100,000 new cases a year worldwide. It has more than 30 partnerships with companies including Lilly, Roche and Takeda.
CI read
The label reaches frontline, but against a modern BTK inhibitor the evidence so far is a response rate.
- The strongest win is against chemotherapy. The 80% risk reduction came against bendamustine plus rituximab. Against a covalent BTK inhibitor, the comparison that matters for most patients, pirtobrutinib has non-inferior response rates and immature survival data.
- Lilly’s partners now meet in CLL. Innovent sells Jaypirca in China, while InnoCare, which signed a discovery deal with Lilly on 24 September, sells the covalent BTK inhibitor orelabrutinib there. A frontline label pits Lilly’s commercial partner against its research partner.
- A broad label for a small population. CLL is uncommon in China, at about 0.39 per 100,000. Covering every line of therapy gives Innovent the whole population, but the absolute numbers are small, so pricing and reimbursement will decide the commercial value.